A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma.
An LC/MS/MS method was developed to quantify carboplatin and eribulin mesylate (E7389) in human plasma and urine. For carboplatin, sample clean-up by protein precipitation and supernatant injection into a Waters Spherisorb((R)) S5 SCX column was used. Liquid-phase extraction and reverse-phase chromatography on a Polaris C18 column were used for eribulin. Quantitation involved LC/MS/MS with positive electrospray ionization. Accuracy, precision, linearity, range, specificity, recovery and stability were also evaluated. Both compounds were stable in human plasma (>or=80 days at -80 degrees C), at room temperature (>or=4h), following three freeze-thaw cycles and in 50/50 methanol/H(2)O (<4 degrees C for >or=252 days).
Drug Safety and Disposition, Eisai Research Institute, 4 Corporate Drive, Andover, MA 01810, USA.
Christopher
C
Desjardins
Phil
P
Saxton
Sharon X
SX
Lu
Xiaofang
X
Li
Christopher
C
Rowbottom
Y Nancy
YN
Wong
D000970:Antineoplastic Agents / Q000097:blood* / Q000652:urine; D016190:Carboplatin / Q000097:blood* / Q000652:urine; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D005663:Furans / Q000097:blood* / Q000652:urine; D006801:Humans; D007659:Ketones / Q000097:blood* / Q000652:urine; D016014:Linear Models; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014044:Tolbutamide / Q000032:analysis; D000095662:Polyether Polyketides
D000970:Antineoplastic Agents; D016190:Carboplatin; D005663:Furans; D007659:Ketones; D014044:Tolbutamide; C490954:eribulin; D000095662:Polyether Polyketides